TW202502371A - 用於治療癌症的與ｂｒａｆ抑制劑的組合療法 - Google Patents

用於治療癌症的與ｂｒａｆ抑制劑的組合療法 Download PDF

Info

Publication number
TW202502371A
TW202502371A TW113121016A TW113121016A TW202502371A TW 202502371 A TW202502371 A TW 202502371A TW 113121016 A TW113121016 A TW 113121016A TW 113121016 A TW113121016 A TW 113121016A TW 202502371 A TW202502371 A TW 202502371A
Authority
TW
Taiwan
Prior art keywords
cancer
seq
combination
polypeptide
braf
Prior art date
Application number
TW113121016A
Other languages
English (en)
Chinese (zh)
Inventor
弗洛克 馬里亞諾 費德里科 紮卡裡亞斯
雅斯特林簡 考爾
蘿拉 蘇切克
Original Assignee
瓦爾希伯倫私人腫瘤研究基金會
卡塔蘭研究和高級研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瓦爾希伯倫私人腫瘤研究基金會, 卡塔蘭研究和高級研究院 filed Critical 瓦爾希伯倫私人腫瘤研究基金會
Publication of TW202502371A publication Critical patent/TW202502371A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW113121016A 2023-06-07 2024-06-06 用於治療癌症的與ｂｒａｆ抑制劑的組合療法 TW202502371A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23382554.6 2023-06-07
EP23382554 2023-06-07

Publications (1)

Publication Number Publication Date
TW202502371A true TW202502371A (zh) 2025-01-16

Family

ID=86732645

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113121016A TW202502371A (zh) 2023-06-07 2024-06-06 用於治療癌症的與ｂｒａｆ抑制劑的組合療法

Country Status (7)

Country Link
EP (1) EP4724083A1 (fr)
KR (1) KR20260020418A (fr)
CN (1) CN121263199A (fr)
AU (1) AU2024285758A1 (fr)
IL (1) IL325025A (fr)
TW (1) TW202502371A (fr)
WO (1) WO2024251854A1 (fr)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
EP1251170A3 (fr) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Procédé et réactif pour le traitement de maladies animales dépendants de NF-kappaB
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
EP2138191A1 (fr) 1998-01-05 2009-12-30 University Of Washington Amélioration du transport par l'utilisation d'agents de rupture de membranes
JP2002537828A (ja) 1999-03-10 2002-11-12 フォゲン リミティド 細胞への物質のデリバリー
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101672664B1 (ko) 2003-07-21 2016-11-04 이뮤노젠 아이엔씨 인간화된 항체 또는 그의 항원결정기 결합절편
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
WO2006135436A2 (fr) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition de l'expression genique et ses usages therapeutiques
SI1912671T1 (en) 2005-07-18 2018-01-31 Seattle Genetics, Inc. Conjugates beta-glucuronide linker-drug
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
HUE027358T2 (en) 2007-11-26 2016-09-28 Bayer Ip Gmbh Anti-mesothelin antibodies and their applications
BRPI0821417A2 (pt) 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
KR101674097B1 (ko) 2008-04-11 2016-11-08 시애틀 지네틱스, 인크. 췌장, 난소 및 다른 암의 검출 및 치료
WO2012041451A1 (fr) 2010-09-29 2012-04-05 Philogen S.P.A. Liant à base de thiazolidine pour la conjugaison de médicaments à des anticorps
HK1202252A1 (en) 2011-11-16 2015-09-25 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
HK1222122A1 (zh) 2013-04-22 2017-06-23 Avelas Biosciences, Inc. 选择性药物递送组合物及使用方法
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
EP3125943B1 (fr) 2014-04-04 2026-04-22 Merck Sharp & Dohme LLC Lieurs à base de phosphates pour introduction intracellulaire de conjugués médicamenteux
US20150342960A1 (en) * 2014-05-29 2015-12-03 Memorial Sloan Kettering Cancer Center Drug combinations for treatment of melanoma and other cancers
TW201609152A (zh) 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物
CN118652192A (zh) 2017-05-24 2024-09-17 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
US20210087238A1 (en) 2017-07-28 2021-03-25 Phylogica Limited Cell penetrating peptides and related compositions and methods
US20200164034A1 (en) * 2018-10-24 2020-05-28 Board Of Regents, The University Of Texas System Methods for improving sex-dimorphic responses to targeted therapy in melanoma
WO2020187998A1 (fr) * 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Polythérapie à l'aide d'omomyc et d'un anticorps se liant à pd-1 ou ctla-4 pour le traitement du cancer

Also Published As

Publication number Publication date
AU2024285758A1 (en) 2025-12-18
KR20260020418A (ko) 2026-02-11
EP4724083A1 (fr) 2026-04-15
CN121263199A (zh) 2026-01-02
AU2024285758A9 (en) 2026-01-15
IL325025A (en) 2026-01-01
WO2024251854A1 (fr) 2024-12-12

Similar Documents

Publication Publication Date Title
JP7684947B2 (ja) 癌の治療のための併用療法
JP2021183618A (ja) 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
TWI908116B (zh) 用於治療癌症的與ｋｒａｓ抑制劑的組合療法
US11566247B2 (en) Modulation of alternative MDM2 splicing
TW202513088A (zh) 用於治療癌症的與ｍｅｋ抑制劑的組合療法
CN121263199A (zh) 用于治疗癌症的与braf抑制剂的组合疗法
TW202421186A (zh) 用於治療癌症的聯合療法
JP2026514551A (ja) がんの治療のための組み合わせ療法
JP2008525005A (ja) 新規の物質、および、それらの使用
WO2007109908A1 (fr) Leures thérapeutiques de la phosphorylation par le yb-1
Hu et al. Tartrate-resistant acid phosphatase 5 serves as a viable target against pulmonary fibrosis by modulating β-catenin signaling
WO2016141269A1 (fr) Kératine 17 en tant que cible diagnostique et thérapeutique pour le cancer
CN101479385A (zh) 用于乳腺癌治疗的hcap18/ll-37抑制剂
JP2020147555A (ja) 抗がん剤抵抗性改善作用を有するクローディン−２結合性短鎖ペプチドの開発
CN101478988A (zh) 联合治疗产品及其应用